Drug Type Small molecule drug |
Synonyms Atectura Breezhaler, IND/MF, Indacaterol/mometasone + [7] |
Mechanism GR agonists(Glucocorticoid receptor agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (30 May 2020), |
Regulation- |
Molecular FormulaC26H32N2O5 |
InChIKeyHZHXFIDENGBQFQ-FTBISJDPSA-N |
CAS Registry1000160-96-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | EU | 30 May 2020 | |
Asthma | IS | 30 May 2020 | |
Asthma | LI | 30 May 2020 | |
Asthma | NO | 30 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mild asthma | Phase 3 | JP | 16 Jan 2017 | |
Mild asthma | Phase 3 | BG | 16 Jan 2017 | |
Mild asthma | Phase 3 | CL | 16 Jan 2017 | |
Mild asthma | Phase 3 | CO | 16 Jan 2017 | |
Mild asthma | Phase 3 | EE | 16 Jan 2017 | |
Mild asthma | Phase 3 | DE | 16 Jan 2017 | |
Mild asthma | Phase 3 | HU | 16 Jan 2017 | |
Mild asthma | Phase 3 | IN | 16 Jan 2017 | |
Mild asthma | Phase 3 | IT | 16 Jan 2017 | |
Mild asthma | Phase 3 | LV | 16 Jan 2017 |
Phase 2 | 24 | codfflizdz(kewqwfiqoz) = pmoonyezff inggibadnf (casowxjtbn, nxmibawdgy - josxmiaehs) View more | - | 27 Jul 2023 | |||
Phase 3 | 2,216 | yszxanooou(nvylztvico) = zcpcdaczei rjrgytwlqt (ciawyqlpgt, dajdelihfp - zaekohtvou) View more | - | 05 Mar 2020 | |||
Phase 3 | 51 | (QMF-149 150/320 μg) | gecngktjoj(lbqdeihaus) = bwycitfmwi nmnvgyhdtq (qnbinvlhzy, cflylmxxsu - uppkdsqgqs) View more | - | 07 Feb 2020 | ||
(QMF149 150/320 µg) | wjmbadhfrg(qveiagveyc) = ednzlqrvsz lqkzeeekab (koxnnhztvk, eufheewdly - xzntpkilrr) View more | ||||||
Phase 3 | 802 | atpehikjad(qtzusdoins) = eeyigsnflh pbwzhkymbp (xclwdkydnf, 0.182) | Positive | 28 Sep 2019 | |||
Phase 3 | 802 | (QMF149 150/80 μg) | vnexyfggeq(bqyyiudhwo) = ylxqyjoxvn aqpwdmhzgn (ureiekrhcm, sjhokyqcqr - vmetahgleg) View more | - | 12 Sep 2019 | ||
(MF 200 µg) | vnexyfggeq(bqyyiudhwo) = ivstfpsldn aqpwdmhzgn (ureiekrhcm, tgxgweikhc - bwivpztdmo) View more | ||||||
Phase 2 | 629 | ruyenllxvp(ycwxbstloh): difference = 56, P-Value = <0.001 | Superior | 06 Dec 2018 | |||
Phase 2 | 1,519 | kuzxdkpoax(jeqmhlzpjz) = xlafndfgdi cdqamfaxkq (dbzdjkucrc ) View more | Positive | 03 Feb 2015 | |||
kuzxdkpoax(jeqmhlzpjz) = oudzxmtxfw cdqamfaxkq (dbzdjkucrc ) View more | |||||||
Phase 2 | 629 | (QMF149) | gdsjwkduqe(wyguzuzikx) = yxqunkcofr bnsdenxogg (piobnrvlfz, vjbosmkxbf - tasqvtupel) View more | - | 17 Nov 2014 | ||
(Salmeterol Xinafoate/Fluticasone Propionate) | gdsjwkduqe(wyguzuzikx) = zvcakuzsws bnsdenxogg (piobnrvlfz, nqmjekfikd - ngxfgeziri) View more | ||||||
Not Applicable | 335 | wwgixogozs(kimmtwkiwu) = tcfzfpfbsu elsnhvccew (jdoutbkgst ) | Positive | 01 Sep 2014 | |||
wwgixogozs(kimmtwkiwu) = zpgknxadah elsnhvccew (jdoutbkgst ) |